Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gruben

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Journal of Comparative Effectiveness Research|February 24, 2025
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Journal of Comparative Effectiveness Research|March 17, 2025
Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Dermatology and Therapy|April 13, 2021
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control StudyFarah Toron, Maureen P Neary, Timothy W Smith, et al.
Arthritis Research & Therapy|March 25, 2026
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United StatesMarina Magrey, Milena A Gianfrancesco, Lara Fallon, et al.
Rheumatology (Oxford, England)|March 2, 2016
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisVibeke Strand, Ronald F van Vollenhoven, Eun Bong Lee, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 31, 2022
Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysisJashin J Wu, Chih-Ho Hong, Joseph F Merola, et al.
Rheumatology and Therapy|November 5, 2023
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled TrialsGustavo Citera, Rakesh Jain, Fedra Irazoque, et al.
ACR Open Rheumatology|October 30, 2025
Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis RegistryJoshua F Baker, Kristi V Mizelle, Wassim Saikali, et al.
Rheumatology and Therapy|September 25, 2024
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking StatusAlexis Ogdie, Lars E Kristensen, Enrique R Soriano, et al.
RMD Open|November 2, 2019
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trialVibeke Strand, Eduardo Mysler, Robert J Moots, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Journal of Comparative Effectiveness Research|February 24, 2025
Matching-adjusted indirect comparisons of efficacy outcomes between etrasimod and ozanimod for moderately to severely active ulcerative colitisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Journal of Comparative Effectiveness Research|March 17, 2025
Efficacy and safety of advanced therapies for moderately to severely active ulcerative colitis in induction and maintenance: systematic literature review and Bayesian network meta-analysisVipul Jairath, Tim Raine, Thomas P Leahy, et al.
Dermatology and Therapy|April 13, 2021
Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control StudyFarah Toron, Maureen P Neary, Timothy W Smith, et al.
Arthritis Research & Therapy|March 25, 2026
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United StatesMarina Magrey, Milena A Gianfrancesco, Lara Fallon, et al.
Rheumatology (Oxford, England)|March 2, 2016
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisVibeke Strand, Ronald F van Vollenhoven, Eun Bong Lee, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 31, 2022
Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysisJashin J Wu, Chih-Ho Hong, Joseph F Merola, et al.
Rheumatology and Therapy|November 5, 2023
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled TrialsGustavo Citera, Rakesh Jain, Fedra Irazoque, et al.
ACR Open Rheumatology|October 30, 2025
Characterization of Second-Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis RegistryJoshua F Baker, Kristi V Mizelle, Wassim Saikali, et al.
Rheumatology and Therapy|September 25, 2024
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking StatusAlexis Ogdie, Lars E Kristensen, Enrique R Soriano, et al.
RMD Open|November 2, 2019
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trialVibeke Strand, Eduardo Mysler, Robert J Moots, et al.
Pageof 7